Related Experiment Video

Updated: Jul 29, 2026

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles
09:01

Programming Stem Cells for Therapeutic Angiogenesis Using Biodegradable Polymeric Nanoparticles

Published on: September 27, 2013

Realizing the Potential of Vascular Targeted Therapy: The Rationale for Combining Vascular Disrupting Agents and

D W Siemann1, D J Chaplin2, M R Horsman3

  • 1a Department of Radiation Oncology , University of Florida , Gainesville , FL , USA.

Cancer Investigation
|September 6, 2017
PubMed

Insights

Vascular targeted therapies (VTTs), including anti-angiogenic agents (AAs) and vascular disrupting agents (VDAs), show promise. Combining AAs and VDAs may offer an effective cancer treatment strategy.

Area of Science:

  • Oncology
  • Vascular Biology
  • Drug Development

Background:

  • Vascular targeted therapies (VTTs) are crucial in cancer treatment, targeting tumor vasculature.
  • VTTs are broadly categorized into anti-angiogenic agents (AAs) and vascular disrupting agents (VDAs).
  • AAs inhibit new blood vessel formation, while VDAs target established tumor vasculature.

Purpose of the Study:

  • To review anti-angiogenic agents (AAs) and vascular disrupting agents (VDAs) in cancer therapy.
  • To explore the rationale and potential of combining AAs and VDAs.
  • To discuss VTTs in monotherapy and combination with conventional treatments.

Main Methods:

  • Literature review of anti-angiogenic agents (AAs) and vascular disrupting agents (VDAs).
  • Analysis of monotherapy and combination treatment strategies involving VTTs.
  • Discussion of the synergistic potential of combined VTT approaches.

Main Results:

  • AAs and VDAs represent distinct yet complementary VTT strategies.
  • Combination therapy with AAs and VDAs holds potential for enhanced efficacy.
  • VTTs can be effectively combined with conventional cancer therapies.

Conclusions:

  • Combined VTT strategies, integrating AAs and VDAs, offer a promising therapeutic avenue.
  • Optimizing VTT combinations may unlock significant advancements in cancer treatment.
  • Further research into combined VTTs is warranted to fully realize their therapeutic potential.
Keywords:
Anti-angiogenic agentcombretastatin A4-phosphatevascular disrupting agentvascular targeted therapy

More Related Videos

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment04:48

Chemotherapy-induced Vascular Toxicity - Real-time In vivo Imaging of Vessel Impairment

Published on: January 7, 2015

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.